As debate continues to rage over the approval and pricing of the Alzheimer’s disease therapy Aduhelm (aducanumab), Biogen Inc. CEO Michel Vounatsos said his firm is “taking a position that is very responsible” but has “yet to be understood out there, and we have to do a better job.”